Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung volume reduction surgery.

Cynthia D Brown1, Henry E Fessler

  • 1Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA. cbrown21@jhmi.edu

COPD
|December 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathogenic CFTR variants as cancer risk modifiers: Findings from the all of us cohort.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025
Same author

Gender Differences in Mental Well-Being Among Children and Adults With Cystic Fibrosis in the Modulator Era.

Pediatric pulmonology·2025
Same author

Enrichment of Germline Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Pathogenic Variants in Patients With Solid Tumors: Evidence for Increased Cancer Risk.

Pediatric pulmonology·2025
Same author

Baseline Characteristics and Self-Reported Use of Chronic Daily Therapies of the Home Reported Outcomes With CFTR Modulator Therapy (HERO-2) Cohort.

Pediatric pulmonology·2025
Same author

Physical well-being and burden of care in adults on modulator therapy: A mixed methods study of patient-reported experiences from the Well-ME survey.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025
Same author

Prevalence of cannabidiol use in persons with cystic fibrosis.

Pediatric pulmonology·2024
Same journal

Global, Regional, and National Burden of COPD Attributable to Secondhand Smoke from 1990 to 2021: Findings from the Global Burden of Disease Study 2021.

COPD·2026
Same journal

Upregulation of LncRNA MIR31HG in COPD Correlates with Disease Severity and Facilitates Inflammation via miR-342-3p.

COPD·2026
Same journal

Methodological Considerations in the Development of the AECOPD "Infection Score".

COPD·2026
Same journal

Barriers and Facilitators to Treatment Plan Adoption and Self-Management in People with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Search and Narrative Synthesis.

COPD·2026
Same journal

Airway Mucus Occlusions in Ex-Smokers with and Without COPD.

COPD·2026
Same journal

Symptom Improvement with BDP/FF/G Fixed Triple Inhalation Powder in Moderate to Severe COPD Patients Uncontrolled with Dual Therapies: A Non-Interventional, Open-Label, Single-Arm, Prospective Study (RESPONSE Slovenia).

COPD·2026
See all related articles

Lung volume reduction surgery (LVRS) offers a treatment for advanced emphysema. This review covers historical context, surgical physiology, and current data on LVRS patient selection, risks, and benefits, including future bronchoscopic techniques.

Area of Science:

  • Pulmonology
  • Thoracic Surgery
  • Medical Technology

Background:

  • Lung volume reduction surgery (LVRS) has been an established treatment for advanced emphysema for a decade.
  • Historical surgical interventions for emphysema provide context for modern approaches.
  • Understanding the physiology of LVRS is crucial for its application.

Purpose of the Study:

  • To review the historical evolution of surgical treatments for emphysema.
  • To present current data on patient selection, risks, and benefits of LVRS.
  • To discuss emerging technologies in bronchoscopic lung volume reduction.

Main Methods:

  • Review of historical surgical attempts for emphysema.
  • Analysis of physiological principles underlying LVRS.

Related Experiment Videos

  • Examination of data from the National Emphysema Treatment Trial (NETT).
  • Inclusion of findings from prior case series and randomized trials.
  • Discussion of future bronchoscopic lung volume reduction technologies.

    • Main Results:

    • The National Emphysema Treatment Trial provides significant data on LVRS outcomes.
    • LVRS has demonstrated benefits in carefully selected patients with advanced emphysema.
    • Historical and contemporary data inform current best practices for LVRS.

    Conclusions:

    • LVRS is a viable treatment option for advanced emphysema, supported by extensive data.
    • Patient selection is critical for optimizing LVRS outcomes.
    • Bronchoscopic lung volume reduction represents a promising future direction.